In contrast to Mdm2, an Mtbp haploinsufficiency did not significantly change the rate of tumor development in wild-type or p53+/− mice, nor did it alter the incidence of p53 mutations/deletions [6]. The gene discussed is MDM2; the disease is neoplasm.